This article is more than 5 years old. Information may no longer be current.
Mitotech initiates phase 3 trial of SkQ1 compound for dry eye
Click Here to Manage Email Alerts
A phase 3 clinical trial of SkQ1 compound Visomitin for dry eye disease has been initiated, Mitotech announced in a press release.
The topical ophthalmic formulation is designed to reduce oxidative stress within the mitochondria, the release said. The phase 3 multicenter, randomized, double-masked, placebo-controlled study will include two SkQ1 treatment arms and a placebo arm.
“Very few drugs with truly innovative mechanisms of action reach this stage of clinical development in dry eye,” Mitotech CEO Natalia Perekhvatova said in the release. “Dry eye disease is a significantly underserved indication, and our company is hoping that this particular study will help deliver a breakthrough product to patients suffering from moderate to severe DED. Dry eye is a multifactorial disease that requires treatment featuring multifactorial mechanism of action, which Visomitin has potential to provide.”
Topline results are expected to be announced in the second quarter of 2019.